resminostat and Hodgkin-Disease

This open-label, single-arm phase II study examined efficacy, safety, pharmacokinetics, and biomarkers of histone deacetylase (HDAC) inhibitor resminostat in patients with relapsed or refractory Hodgkin lymphoma. Thirty-seven heavily pretreated patients received 600 (19 patients) or 800 mg (18 patients) oral resminostat daily for the initial 5 days of 14-day treatment cycles. Objective response rate (ORR) (primary) was 34% reaching disease control in 54% patients. Most patients (69%) showed reduced tumor size and reduced [

Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Drug Resistance, Neoplasm; Female; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Recurrence; Retreatment; Sulfonamides; Treatment Outcome; Young Adult